ArticleCancer reports (Hoboken, N.J.)2025
Sonographic Correlations With Histological Grade and Biomarker Profiles in Breast Invasive Ductal Carcinoma.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Complex Path from Mammary Ductal Hyperplasia to Breast Cancer: Elevated Malignancy Risk in Atypical Forms.Biomedicines · 2026Review
- Sonographic Correlations With Histological Grade and Biomarker Profiles in Breast Invasive Ductal Carcinoma.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive ductal carcinoma (IDC), the most common breast cancer subtype, exhibits significant heterogeneity, limiting traditional prognostic markers. Molecular profiles improve precision, but imaging features may also reflect tumor biology.
aimsThis study evaluates the predictive potential and clinical applicability of ultrasound features for determining tumor grade and molecular profiles in IDC. METHODS AND
resultsA blinded radiologist retrospectively analyzed 109 IDC cases using the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) classification, evaluating ultrasound features such as lesion shape, margins, orientation, echo pattern, calcifications, vascularity, and lymph node involvement. Tumors were graded histologically (Scarff-Bloom-Richardson system) as low (grades 1 and 2) or high (grade 3). Immunohistochemistry determined estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 status. ER and PR positivity were defined as > 10% nuclear staining, HER2 graded on a 0-3+ scale, and Ki-67 positivity as ≥ 10% staining. Statistical analyses, including logistic and linear regression, examined correlations between ultrasound features and histological/molecular profiles. Among 109 women (mean age 48.4 ± 12.5 years), the mean tumor length and width were 21.83 ± 11.22 mm and 15.3 ± 6.97 mm, respectively. Histopathological grading revealed that grade 2 tumors were predominant (51%), while grade 1 and grade 3 tumors were observed in 25% and 24% of cases, respectively. ER and PR positivity were observed in 76.4% and 67.6% of cases, respectively. High-grade tumors were significantly associated with ER and PR negativity (p-value < 0.05). Ultrasound features associated with high-grade tumors included larger tumor length (p-value = 0.029). ER positive tumors had smaller axillary lymph nodes (p-value < 0.05). Likewise, PR positive tumors exhibited smaller suspicious axillary lymph nodes compared to PR negative cases (p-value = 0.004).
conclusionSonographic features may correlate with histological grades and hormone receptor statuses in breast IDC, suggesting that ultrasound could aid in predictive assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.